Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia

Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia

Patients with NPM1 gene mutation-associated acute myeloid leukemia (AML), particularly those over the age of 60, have no viable targeted therapeutic choices. In this study, we identified HEN-463, a sesquiterpene lactone derivative specific targets AML with this gene mutation. This compound inhibits...

Full description

Bibliographic Details
Main Authors: Yefan Han, Anni Hu, Yi Qu, Qianqian Xu, Hang Wang, Yin Feng, Yili Hu, Li He, Hao Wu, Xinzhi Wang
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Pharmacological Research
Subjects:
AML
NPM1 mutation
LAS1-NOL9 axis
Covalent inhibitor
Ribosome biogenesis
RRNA maturation
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661823000567

Internet

http://www.sciencedirect.com/science/article/pii/S1043661823000567

Similar Items